Previous 10 | Next 10 |
2023-03-23 10:17:23 ET The NASDAQ Stock Market notified Entera Bio ( NASDAQ: ENTX ) that it has regained compliance with the minimum bid price requirement. In November 2022, the company was notified that its shares had failed to maintain a minimum bid price of $1 in p...
JERUSALEM, March 23, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced today that it received notice from The NASDAQ Stock Market LLC...
2023-03-07 12:39:41 ET Gainers: ThredUp ( TDUP ) +73% . WW International ( WW ) +49% . Unicycive ( UNCY ) +39% . Protagonist Therapeutics ( PTGX ) +32% . Bionomics ( BNOX ) +28% . Novo Integrated Sciences ( NVOS ) +25% ...
2023-03-07 11:28:43 ET Gainers: Unicycive ( UNCY ) +52% . Bionomics ( BNOX ) +49% . Novo Integrated Sciences ( NVOS ) +37% . Protagonist Therapeutics ( PTGX ) +34% . Allakos ( ALLK ) +22% . Losers: Cara ( CARA ) -28...
2023-03-07 08:27:38 ET Cara Therapeutics CARA -28% on Q4 results. Appreciate Holdings ( SFR ) -16% . Tremor International TRMR -12% on Q4 results. THOR Industries THO -11% on Q2 results. Ambrx Biopharma ( AMAM ) -9% . Avalon ...
2023-03-06 13:05:55 ET Gainers: Bellerophon ( BLPH ) +86% . Ambrx Biopharma ( AMAM ) +69% . BridgeBio Pharma ( BBIO ) +56% . Avalon GloboCare ( ALBT ) +47% . Azul ( AZUL ) +42% . TCR2 Therapeutics ( TCRR ) +38% . ...
2023-03-06 08:32:34 ET BridgeBio Pharma ( BBIO ) +57% Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events. TCR2 Therapeutics ...
Entera Bio ( NASDAQ: ENTX ) is up ~9% in Wednesday morning trading after saying that the US FDA has agreed to a Type D meeting protocol review to finalize the phase 3 trial design of a candidate for post-menopausal osteoporosis. The study, proposed to last 24 months, would evaluat...
Type D meeting protocol submission builds on concurrence reached with FDA following successful Type C meeting and supports potential Phase 3 initiation in H2 2023 JERUSALEM, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company&...
JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a late-clinical stage, leader in the development of orally delivered peptides and therapeutic proteins, today announced that the Company will participate in the SVB...
News, Short Squeeze, Breakout and More Instantly...